04:11 AM EDT, 05/20/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday it plans to build its first end-to-end manufacturing facility to produce antibody drug conjugates in Singapore for $1.5 billion.

The drugmaker has a broad portfolio of in-house ADCs, treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. Six are wholly owned in clinical development, and more are in pre-clinical development.

Construction on the facility, which is designed to emit zero carbon, will begin by the end of 2024 and it will be operationally ready by 2029.

The facility is built in support of the Singapore Economic Development Board.

Price: 76.75, Change: -0.15, Percent Change: -0.20